FTO inhibits the expression of ASB2 and RARA by reducing m6A levels of the target mRNA, which in turn enhances leukemic oncogene-mediated cell transformation and leukemogenesis, and inhibits all-trans retinoic acid (ATRA)-induced AML cell differentiation (Li et al., 2017). Here, RARA is linked to acute myeloid leukemia.